Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: Implications for neuropsychiatric diseases

Neurobiology of Disease

Volumn 63, Issue , 2014, Pages 129-140

  Lin, Hong ^a   Hsu, Fu Chun ^a   Baumann, Bailey H ^a   Coulter, Douglas A ^a,b   Lynch, David R ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cortex; D serine; Extrasynaptic NMDA receptor; Glutamatergic synaptic deficits; Neuropsychiatric diseases; Schizophrenia; Serine racemase; Synaptic NMDA receptor; 7 nicotinic acetylcholine receptor; 7 KO

Indexed keywords

BUNGAROTOXIN RECEPTOR; DEXTRO SERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RACEMASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL CULTURE; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MENTAL DISEASE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; POSTNATAL DEVELOPMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; SYNAPSE;

CORTEX; D-SERINE; EXTRASYNAPTIC NMDA RECEPTOR; GLUTAMATERGIC SYNAPTIC DEFICITS; N-METHYL-D-ASPARTATE RECEPTOR; NACHR; NEUROPSYCHIATRIC DISEASES; NICOTINIC ACETYLCHOLINE RECEPTOR; NMDAR; SCHIZOPHRENIA; SERINE RACEMASE; SR; SYNAPTIC NMDA RECEPTOR; VESICULAR GLUTAMATE TRANSPORTER 1; VGLUT1; WILD-TYPE; WT; Α7 NACHR NULL; Α7 NICOTINIC ACETYLCHOLINE RECEPTOR; Α7-KO;

AGE FACTORS; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GUANYLATE KINASE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PREGNANCY; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84890879661     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.11.021     Document Type: Article

References (61)

1. Adams C.E., Yonchek J.C., Schulz K.M., Graw S.L., Stitzel J., Teschke P.U., Stevens K.E. Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases. Neuroscience 2012, 207:274-282.
2. Ancin I., Cabranes J.A., Santos J.L., Sanchez-Morla E., Vazquez-Alvarez B., Rodriguez-Moya L., Pousada-Casal A., Fernandez C., Aparicio A., Barabash A. CHRNA7 haplotypes are associated with impaired attention in euthymic bipolar disorder. J. Affect. Disord. 2011, 133:340-345.
3. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., Bolshakov V.Y., Coyle J.T. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2400-E2409.
4. Basu A.C., Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., Jiang Z.I., Benneyworth M.A., Froimowitz M.P., Lange N., Snyder S.H., Bergeron R., Coyle J.T. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 2009, 14:719-727.
5. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
6. Bitanihirwe B.K., Lim M.P., Kelley J.F., Kaneko T., Woo T.U. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 2009, 9:71.
7. Brown K.L., Comalli D.M., De Biasi M., Woodruff-Pak D.S. Trace eyeblink conditioning is impaired in alpha7 but not in beta2 nicotinic acetylcholine receptor knockout mice. Front. Behav. Neurosci. 2010, 4:166.
8. Cannon C.E., Puri V., Vivian J.A., Egbertson M.S., Eddins D., Uslaner J.M. The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology 2013, 64:191-196.
9. Carlen M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., Ruhlmann C., Jones S.R., Deisseroth K., Sheng M., Moore C.I., Tsai L.H. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol. Psychiatry 2012, 17:537-548.
10. Coyle J.T. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 2012, 38:920-926.
11. Coyle J.T., Basu A., Benneyworth M., Balu D., Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb. Exp. Pharmacol. 2012, 267-295.
12. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
13. Dong Y.N., Waxman E.A., Lynch D.R. Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit control calpain-mediated cleavage of the NMDA receptor. J. Neurosci. 2004, 24:11035-11045.
14. Endris V., Hackmann K., Neuhann T.M., Grasshoff U., Bonin M., Haug U., Hahn G., Schallner J.C., Schrock E., Tinschert S., Rappold G., Moog U. Homozygous loss of CHRNA7 on chromosome 15q13.3 causes severe encephalopathy with seizures and hypotonia. Am. J. Med. Genet. A 2010, 152A:2908-2911.
15. Fernandes C., Hoyle E., Dempster E., Schalkwyk L.C., Collier D.A. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav. 2006, 5:433-440.
16. Girod R., Barazangi N., McGehee D., Role L.W. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 2000, 39:2715-2725.
17. Hajos M., Rogers B.N. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr. Pharm. Des. 2010, 16:538-554.
18. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
19. Helbig I., et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat. Genet. 2009, 41:160-162.
20. Hellier J.L., Arevalo N.L., Smith L., Xiong K.N., Restrepo D. alpha7-Nicotinic acetylcholine receptor: role in early odor learning preference in mice. PLoS ONE 2012, 7:e35251.
21. Hoftman G.D., Lewis D.A. Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. Schizophr. Bull. 2011, 37:493-503.
22. Hoppman-Chaney N., Wain K., Seger P., Superneau D., Hodge J. Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype. Clin. Genet. 2013, 83:345-351.
23. Javitt D.C. Twenty-five years of glutamate in schizophrenia: are we there yetα. Schizophr. Bull. 2012, 38:911-913.
24. Karpova A., Mikhaylova M., Bera S., Bar J., Reddy P.P., Behnisch T., Rankovic V., Spilker C., Bethge P., Sahin J., Kaushik R., Zuschratter W., Kahne T., Naumann M., Gundelfinger E.D., Kreutz M.R. Encoding and transducing the synaptic or extrasynaptic origin of NMDA receptor signals to the nucleus. Cell 2013, 152:1119-1133.
25. Kaufman A.M., Milnerwood A.J., Sepers M.D., Coquinco A., She K., Wang L., Lee H., Craig A.M., Cynader M., Raymond L.A. Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J. Neurosci. 2012, 32:3992-4003.
26. Korotkova T., Fuchs E.C., Ponomarenko A., von Engelhardt J., Monyer H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 2010, 68:557-569.
27. Labrie V., Wong A.H., Roder J.C. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 2012, 62:1484-1503.
28. Lepichon J.B., Bittel D.C., Graf W.D., Yu S. A 15q13.3 homozygous microdeletion associated with a severe neurodevelopmental disorder suggests putative functions of the TRPM1, CHRNA7, and other homozygously deleted genes. Am. J. Med. Genet. A 2010, 152A:1300-1304.
29. Levin E.D., Petro A., Rezvani A.H., Pollard N., Christopher N.C., Strauss M., Avery J., Nicholson J., Rose J.E. Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav. Brain Res. 2009, 196:207-213.
30. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
31. Liao J., DeWard S.J., Madan-Khetarpal S., Surti U., Hu J. A small homozygous microdeletion of 15q13.3 including the CHRNA7 gene in a girl with a spectrum of severe neurodevelopmental features. Am. J. Med. Genet. A 2011, 155A:2795-2800.
32. Lin H., Vicini S., Hsu F.C., Doshi S., Takano H., Coulter D.A., Lynch D.R. Axonal alpha7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16661-16666.
33. Liu Z., Conroy W.G., Stawicki T.M., Nai Q., Neff R.A., Berg D.K. EphB receptors co-distribute with a nicotinic receptor subtype and regulate nicotinic downstream signaling in neurons. Mol. Cell. Neurosci. 2008, 38:236-244.
34. Lozada A.F., Wang X., Gounko N.V., Massey K.A., Duan J., Liu Z., Berg D.K. Glutamatergic synapse formation is promoted by alpha7-containing nicotinic acetylcholine receptors. J. Neurosci. 2012, 32:7651-7661.
35. Ma T.M., Abazyan S., Abazyan B., Nomura J., Yang C., Seshadri S., Sawa A., Snyder S.H., Pletnikov M.V. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via d-serine depletion. Mol. Psychiatry 2013, 18:557-567.
36. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14:301-307.
37. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
38. Mathew S.V., Law A.J., Lipska B.K., Davila-Garcia M.I., Zamora E.D., Mitkus S.N., Vakkalanka R., Straub R.E., Weinberger D.R., Kleinman J.E., Hyde T.M. Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum. Mol. Genet. 2007, 16:2921-2932.
39. Miller D.T., et al. Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J. Med. Genet. 2009, 46:242-248.
40. Monnerie H., Hsu F.C., Coulter D.A., Le Roux P.D. Role of the NR2A/2B subunits of the N-methyl-d-aspartate receptor in glutamate-induced glutamic acid decarboxylase alteration in cortical GABAergic neurons in vitro. Neuroscience 2010, 171:1075-1090.
41. Nolt M.J., Lin Y., Hruska M., Murphy J., Sheffler-Colins S.I., Kayser M.S., Passer J., Bennett M.V., Zukin R.S., Dalva M.B. EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J. Neurosci. 2011, 31:5353-5364.
42. Olincy A., Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor. Handb. Exp. Pharmacol. 2012, 211-232.
43. Papouin T., Ladepeche L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L., Pollegioni L., Mothet J.P., Oliet S.H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
44. Rotaru D.C., Yoshino H., Lewis D.A., Ermentrout G.B., Gonzalez-Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J. Neurosci. 2011, 31:142-156.
45. Rotaru D.C., Lewis D.A., Gonzalez-Burgos G. The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia. Rev. Neurosci. 2012, 23:97-109.
46. Sanz-Clemente A., Nicoll R.A., Roche K.W. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist 2013, 19:62-75.
47. Schwartz T.L., Sachdeva S., Stahl S.M. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr. Pharm. Des. 2012, 18:1580-1592.
48. Sharp A.J., et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat. Genet. 2008, 40:322-328.
49. Shinawi M., Schaaf C.P., Bhatt S.S., Xia Z., Patel A., Cheung S.W., Lanpher B., Nagl S., Herding H.S., Nevinny-Stickel C., Immken L.L., Patel G.S., German J.R., Beaudet A.L., Stankiewicz P. A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat. Genet. 2009, 41:1269-1271.
50. Spielmann M., Reichelt G., Hertzberg C., Trimborn M., Mundlos S., Horn D., Klopocki E. Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings. Eur. J. Med. Genet. 2011, 54:e441-e445.
51. Timofeeva O.A., Levin E.D. Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience 2011, 195:21-36.
52. Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Hansen K.B., Yuan H., Myers S.J., Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010, 62:405-496.
53. Tregellas J.R., Tanabe J., Rojas D.C., Shatti S., Olincy A., Johnson L., Martin L.F., Soti F., Kem W.R., Leonard S., Freedman R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 2011, 69:7-11.
54. Wallace T.L., Porter R.H. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem. Pharmacol. 2011, 82:891-903.
55. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
56. Wolosker H., Blackshaw S., Snyder S.H. Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13409-13414.
57. Yasui D.H., Scoles H.A., Horike S., Meguro-Horike M., Dunaway K.W., Schroeder D.I., Lasalle J.M. 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Hum. Mol. Genet. 2011, 20:4311-4323.
58. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., Finlayson K., Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol. 2007, 17:145-155.
59. Young J.W., Meves J.M., Tarantino I.S., Caldwell S., Geyer M.A. Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011, 10:720-733.
60. Zhang L., Warren R.A. Muscarinic and nicotinic presynaptic modulation of EPSCs in the nucleus accumbens during postnatal development. J. Neurophysiol. 2002, 88:3315-3330.
61. Zheng C.Y., Seabold G.K., Horak M., Petralia R.S. MAGUKs, synaptic development, and synaptic plasticity. Neuroscientist 2011, 17:493-512.